# EDGAR Filing Document

**Accession Number:** 0002104976
**File Stem:** 0001193125-26-089500
**Filing Date:** 2026-3
**Character Count:** 14396
**Document Hash:** a1f045796f4e8c19f0861b5667c94ea0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-089500.hdr.sgml**: 20260303

**ACCESSION NUMBER**: 0001193125-26-089500

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260227

**FILED AS OF DATE**: 20260303

**DATE AS OF CHANGE**: 20260303

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Gaines Scott
- **CENTRAL INDEX KEY:** 0002104976

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40690
- **FILM NUMBER:** 26718338

**MAIL ADDRESS:**
- **STREET 1:** C/O RXSIGHT, INC.
- **STREET 2:** 100 COLUMBIA
- **CITY:** ALISO VIEJO
- **STATE:** CA
- **ZIP:** 92656
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RxSight, Inc.
- **CENTRAL INDEX KEY:** 0001111485
- **STANDARD INDUSTRIAL CLASSIFICATION:** OPHTHALMIC GOODS [3851]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 943268801
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 100 COLUMBIA STREET
- **STREET 2:** SUITE 120
- **CITY:** ALISO VIEJO
- **STATE:** CA
- **ZIP:** 92656
- **BUSINESS PHONE:** 949-521-7822

**MAIL ADDRESS:**
- **STREET 1:** 100 COLUMBIA STREET
- **STREET 2:** SUITE 120
- **CITY:** ALISO VIEJO
- **STATE:** CA
- **ZIP:** 92656

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CALHOUN VISION INC
- **DATE OF NAME CHANGE:** 20000410

## Ex-24

**POWER OF ATTORNEY**

Know all by these presents, that the undersigned hereby constitutes and appoints each of Ron Kurtz, Mark Wilterding, Jim Schindler, Glebb Popov, Martin J. Waters, Robert L. Wernli, Jr., Bridget Balisy and Trevor Dorne, or either of them acting singly, and with full power of substitution and re-substitution, the undersigned's true and lawful attorney-in-fact (each of such persons and their substitutes being referred to herein as the "Attorney-in-Fact"), with full power to act for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Prepare, execute and submit to the Securities and Exchange Commission ("SEC"), RxSight, Inc. (the "Company"), and/or any national securities exchange on which the Company's securities are listed any and all reports (including any amendments thereto) the undersigned is required to file with the SEC, or which the Attorney-in-Fact considers it advisable to file with the SEC, under Section 13 or Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act") or any rule or regulation thereunder, or under Rule 144 under the Securities Act of 1933 ("Rule 144"), with respect to any security of the Company, including Forms 3, 4 and 5, Schedules 13D and 13G, and Forms 144; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's equity securities from any third party, including the Company and any brokers, dealers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such third party to release any such information to the Attorney-in-Fact.

The undersigned acknowledges that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)This Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act in his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any documents prepared or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his or her discretion, deems necessary or desirable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Neither the Company nor the Attorney-in-Fact assumes any liability for the undersigned's responsibility to comply with the requirements of Section 13 or Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section 13 or Section 16 of the Exchange Act, including, without limitation, the reporting requirements under Section 13 or Section 16 of the Exchange Act.

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or advisable to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by authority of this Power of Attorney.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 4 or 5 or Schedules 13D or 13G or Forms 144 with respect to the undersigned's holdings of and transactions in securities of the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact. This Power of Attorney revokes all previous powers of attorney with respect to the subject matter of this Power of Attorney.

------

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed on February 25, 2026.

Signature: /s/ Scott Gaines

Print Name: Scott Gaines

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Gaines Scott<br><sub>(Last) (First) (Middle)</sub><br>100 COLUMBIA<br><sub>(Street)</sub><br>ALISO VIEJO, CA 92656<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-27 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Customer Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>RxSight, Inc. [ RXST ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-28 |  | M |  | 6261 | A | <sup>(1)</sup> | 17428 | D |  |
| Common Stock | 2026-02-28 |  | F |  | 2580 | D | $7.61 | 14848 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-02-27 |  | A |  | 32218 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 32218 | $0 | 32218 | D |  |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-02-28 |  | M |  |  | 1500 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 1500 | $0 | 3000 | D |  |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-02-28 |  | M |  |  | 604 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 604 | $0 | 2414 | D |  |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-02-28 |  | M |  |  | 1250 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 1250 | $0 | 6250 | D |  |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-02-28 |  | M |  |  | 1657 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 1657 | $0 | 9936 | D |  |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-02-28 |  | M |  |  | 1250 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 1250 | $0 | 2500 | D |  |

---

### Footnotes:

(1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

(2) Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan (the "Plan")) through each applicable date, one-sixth (1/6th) of the RSUs subject to the award shall vest on the first Trading Day (as defined in the Plan) on or after each of August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028 and February 28, 2029.

(3) Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, one-eighth (1/8th) of the RSUs subject to the award shall vest on the first Trading Day (as defined in the Plan) on or after each of August 31, 2023, February 29, 2024, August 31, 2024, February 28, 2025, August 31, 2025, February 28, 2026, August 31, 2026 and February 28, 2027. Of the 12,000 RSUs initially subject to the award, 7,500 shares subject to the award vested prior to the Reporting Person becoming a Section 16 executive officer.

(4) Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, one-eighth (1/8th) of the RSUs subject to the award shall vest on the first Trading Day (as defined in the Plan) on or after each of August 31, 2024, February 28, 2025, August 31, 2025, February 28, 2026, August 31, 2026, February 28, 2027, August 31, 2027 and February 29, 2028. Of the 4,830 RSUs initially subject to the award, 1,812 shares subject to the award vested prior to the Reporting Person becoming a Section 16 executive officer.

(5) Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, one-eighth (1/8th) of the RSUs subject to the award shall vest on the first Trading Day (as defined in the Plan) on or after each of February 28, 2025, August 31, 2025, February 28, 2026, August 31, 2026, February 28, 2027, August 31, 2027, February 29, 2028 and August 31, 2028. Of the 10,000 RSUs initially subject to the award, 2,500 shares subject to the award vested prior to the Reporting Person becoming a Section 16 executive officer.

(6) Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, one-eighth (1/8th) of the RSUs subject to the award shall vest on the first Trading Day (as defined in the Plan) on or after each of August 31, 2025, February 28, 2026, August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028 and February 28, 2029. Of the 13,250 RSUs initially subject to the award, 1,657 shares subject to the award vested prior to the Reporting Person becoming a Section 16 executive officer.

(7) Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, one-fourth (1/4th) of the RSUs subject to the award shall vest on the first Trading Day (as defined in the Plan) on or after each of August 31, 2025, February 28, 2026, August 31, 2026, February 28, 2027. Of the 5,000 RSUs initially subject to the award, 1,250 shares subject to the award vested prior to the Reporting Person becoming a Section 16 executive officer.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Jim Schindler, as Attorney-in-Fact  
**Date:** 2026-03-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**